Surrozen (SRZN) FDA Approvals $29.98 -2.34 (-7.24%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$29.08 -0.91 (-3.02%) As of 08:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Surrozen's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Surrozen (SRZN). Over the past two years, Surrozen has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as SZN-8141. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. SZN-8141 FDA Regulatory Events SZN-8141 is a drug developed by Surrozen for the following indication: for the Treatment of Diabetic Macular Edema. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - October 2,2026Provided Update INDDrug: SZN-8141Announced Date: October 2, 2026Indication: for the Treatment of Diabetic Macular EdemaAnnouncementSurrozen, Inc announced its Investigational New Drug (IND) application for SZN-8141 has become effective, enabling the Company to advance the program into clinical development. SZN-8141 is a bifunctional Wnt agonist and vascular endothelial growth factor (VEGF) antagonist antibody being developed as an intravitreal injection for the treatment of diabetic macular edema (DME).AI SummarySurrozen, Inc. announced that its Investigational New Drug (IND) application for SZN-8141 is effective, allowing the company to move the treatment into clinical testing. SZN-8141 is an antibody designed to both activate Wnt signaling and block vascular endothelial growth factor (VEGF). Surrozen is developing it as an injection into the eye for diabetic macular edema (DME), a condition that can threaten vision. The company expects to give the first patient a dose in the DUET Phase 1b/2a study in the fourth quarter of 2026. The study will assess safety, tolerability, and early signs of activity. Its later stage is expected to compare two SZN-8141 dose levels with Vabysmo in about 60 patients who have not previously received treatment for DME. Initial study results are expected in the second half of 2027. The IND milestone also meets a condition for a second private-placement closing, expected to provide about $95.1 million in gross proceeds to support development of SZN-8141, SZN-8143, and company operations.Read Announcement Surrozen FDA Events - Frequently Asked Questions Has Surrozen received FDA approval? As of now, Surrozen (SRZN) has not received any FDA approvals for its therapy in the last two years. What drugs has Surrozen submitted to the FDA? In the past two years, Surrozen (SRZN) has reported FDA regulatory activity for SZN-8141. What is the most recent FDA event for Surrozen? The most recent FDA-related event for Surrozen occurred on October 2, 2026, involving SZN-8141. The update was categorized as "Provided Update," with the company reporting: "Surrozen, Inc announced its Investigational New Drug (IND) application for SZN-8141 has become effective, enabling the Company to advance the program into clinical development. SZN-8141 is a bifunctional Wnt agonist and vascular endothelial growth factor (VEGF) antagonist antibody being developed as an intravitreal injection for the treatment of diabetic macular edema (DME)." What conditions do Surrozen's current drugs treat? Currently, Surrozen has one therapy (SZN-8141) targeting the following condition: for the Treatment of Diabetic Macular Edema. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Innate Pharma FDA EventsRecursion Pharmaceuticals FDA EventsSummit Therapeutics FDA EventsACADIA Pharmaceuticals FDA EventsBiogen FDA EventsEikon Therapeutics FDA EventsGain Therapeutics FDA EventsIonis Pharmaceuticals FDA EventsKaryopharm Therapeutics FDA EventsPulmonx FDA EventsMetaVia FDA EventsNeonc Technologies FDA EventsRegeneron Pharmaceuticals FDA EventsSELLAS Life Sciences Group FDA EventsSanofi FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Beam Therapeutics FDA Events Celldex Therapeutics FDA Events Lakefront Biotherapeutics American Depositary Shares FDA Events Immunome FDA Events Pharvaris FDA Events Biohaven FDA Events Replimune Group FDA Events Vera Therapeutics FDA Events Septerna FDA Events Recursion Pharmaceuticals FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:SRZN last updated on 10/2/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surrozen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surrozen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - October 2,2026Provided Update INDDrug: SZN-8141Announced Date: October 2, 2026Indication: for the Treatment of Diabetic Macular EdemaAnnouncementSurrozen, Inc announced its Investigational New Drug (IND) application for SZN-8141 has become effective, enabling the Company to advance the program into clinical development. SZN-8141 is a bifunctional Wnt agonist and vascular endothelial growth factor (VEGF) antagonist antibody being developed as an intravitreal injection for the treatment of diabetic macular edema (DME).AI SummarySurrozen, Inc. announced that its Investigational New Drug (IND) application for SZN-8141 is effective, allowing the company to move the treatment into clinical testing. SZN-8141 is an antibody designed to both activate Wnt signaling and block vascular endothelial growth factor (VEGF). Surrozen is developing it as an injection into the eye for diabetic macular edema (DME), a condition that can threaten vision. The company expects to give the first patient a dose in the DUET Phase 1b/2a study in the fourth quarter of 2026. The study will assess safety, tolerability, and early signs of activity. Its later stage is expected to compare two SZN-8141 dose levels with Vabysmo in about 60 patients who have not previously received treatment for DME. Initial study results are expected in the second half of 2027. The IND milestone also meets a condition for a second private-placement closing, expected to provide about $95.1 million in gross proceeds to support development of SZN-8141, SZN-8143, and company operations.Read Announcement